Navigation Links
Prometic provides information for its Annual and Special Meeting of Shareholders
Date:5/1/2008

MONTREAL, May 1 /PRNewswire-FirstCall/ - ProMetic Life Sciences Inc. ("ProMetic") (TSX:PLI) will host its Annual and Special Meeting of Shareholders on Wednesday, May 7, 2008 at 10:30 a.m. (EDT). The Annual and Special Meeting of Shareholders ("Meeting") will be held at the Montreal Museum of Fine Arts located at 1379 Sherbrooke Street West in Montreal. Points to be covered are:

- Items on the Meeting's agenda as per the Management Information

Circular

- Corporate Presentations

- MacoPharma presents update on launch of P-Capt(R) prion capture

filter

- Protein Technologies business update

- Anemia drugs program update - PBI-1402 and analogues

- Corporate strategy to build shareholder value

Following these presentations shareholders and guests will have the opportunity of viewing displays on ProMetic's various products, as well as meeting members of management and scientists who will be gathered for the occasion.

For those who are unable to attend in person, the Company will offer a live audio webcast through ProMetic's website at http://www.prometic.com. A replay of the webcast will be available following the meeting on ProMetic's website.

About ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc. ("ProMetic") (http://www.prometic.com) is a biopharmaceutical company specialized in the research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic Ligand(TM) technology. This technology is used in large-scale purification of biologics and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission to bring to market effective, innovative, lower cost, less toxic products for the treatment of hematology and cancer. Its drug discovery platform is focused on replacing complex, expensive proteins with synthetic "drug-like" protein mimetics. Headquartered in Montreal (Canada), ProMetic has R&D facilities in the U.K., the U.S. and Canada, manufacturing facilities in the U.K. and business development activities in the US, Europe, Asia and in the Middle-East.

Forward Looking Statements

This press release contains forward-looking statements about ProMetic's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, ProMetic's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of ProMetic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations on page 21 of ProMetic's Annual Information Form for the year ended December 31, 2007, under the heading "Risk Factors". As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.


'/>"/>
SOURCE PROMETIC LIFE SCIENCES INC.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ProMetic presents preclinical data for prostate and pancreatic cancer at the AACR Meeting
2. ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc.
3. Prometic to present at the American Chemical Society
4. ProMetic and Sartorius Stedim Biotech collaborate on technology transfer deals in Asia
5. ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia
6. ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products
7. ProMetic provides business update - Over $35 million worth of business secured in January
8. ProMetic announces scale-up of prion removal resin in plasma product for biopharmaceutical use
9. ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies
10. AEterna Zentaris Partner, Spectrum, Provides Update on Ozarelix in Benign Prostatic Hyperplasia
11. Genzyme Provides Update on Myozyme(R) Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... The publishing industry ... Access publishing is one of the popular publication models that has received wider ... and 3000+ International Conferences across the globe, OMICS International is ...
(Date:2/9/2016)...  DNAtrix, a clinical stage, biotechnology company ... its lead product, DNX-2401, has been designated ... medicinal product for the treatment of glioma. ... approximately 25,000 people a year in the ... --> http://photos.prnewswire.com/prnh/20160208/330986LOGO ...
(Date:2/9/2016)... BOSTON and LONDON , February ... see leading bio tech replace paper and ... The web-based electronic laboratory notebook (ELN) will be rolled out ... replace paper-based research and development (R&D) and protect valuable IP. ... time and follow a specific researcher or experiment as part ...
(Date:2/9/2016)... , Feb. 9, 2016 BERG, ... data-driven, biological research approach, has announced the appointment ... Officer and Chief Operating Officer. Haddock brings to ... finance, including 12 years in senior financial functions ... experience in business organizational management. ...
Breaking Biology Technology:
(Date:2/2/2016)... 2016   Parabon NanoLabs (Parabon) announced ... Research Office and the Defense Forensics and Biometrics ... the company,s Snapshot Kinship Inference software ... generally, defense-related DNA forensics.  Although Snapshot is best ... and ancestry from DNA evidence), it also has ...
(Date:2/1/2016)... wallet ( www.wocketwallet.com ) announces the launch of a new video featuring ... Las Vegas , where Joey appeared at the Wocket booth ... , where Joey appeared at the Wocket booth to meet and ... at the Consumer Electronics Show (CES2016) in Las Vegas ... fans. --> --> The video ...
(Date:1/25/2016)... 25, 2016  Glencoe Software, the world-leading supplier of ... industries, will provide the data management solution OMERO Plus ... Photo - ... Phenotypic analysis measures the characteristics and ... comparisons between states such as health and disease, the ...
Breaking Biology News(10 mins):